Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2015/412903 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849435203961880576 |
|---|---|
| author | Alfredo García-Layana Marta S. Figueroa Luis Arias Javier Araiz José María Ruiz-Moreno José García-Arumí Francisco Gómez-Ulla María Isabel López-Gálvez Francisco Cabrera-López José Manuel García-Campos Jordi Monés Enrique Cervera Felix Armadá Roberto Gallego-Pinazo |
| author_facet | Alfredo García-Layana Marta S. Figueroa Luis Arias Javier Araiz José María Ruiz-Moreno José García-Arumí Francisco Gómez-Ulla María Isabel López-Gálvez Francisco Cabrera-López José Manuel García-Campos Jordi Monés Enrique Cervera Felix Armadá Roberto Gallego-Pinazo |
| author_sort | Alfredo García-Layana |
| collection | DOAJ |
| description | Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the patient is treated in the presence of signs of lesion activity. Therefore, an early detection of reactivation of the disease with immediate retreatment is crucial to prevent visual acuity loss. Several trials suggest that “treat and extend” and other proactive regimens provide a reasonable approach. The rationale of the proactive regimens is to perform treatment anticipating relapses or recurrences and therefore avoid drops in vision while individualizing patient followup. Treat and extend study results in significant direct medical cost savings from fewer treatments and office visits compared to monthly treatment. Current data suggest that, for one year, PRN is less expensive, but treat and extend regimen would likely be less expensive for subsequent years. Once a patient is not a candidate to continue with treatment, he/she should be sent to an outpatient unit with adequate resources to follow nAMD patients in order to reduce the burden of specialized ophthalmologist services. |
| format | Article |
| id | doaj-art-df4c754bab5a4152866b9d95b0654703 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-df4c754bab5a4152866b9d95b06547032025-08-20T03:26:21ZengWileyJournal of Ophthalmology2090-004X2090-00582015-01-01201510.1155/2015/412903412903Individualized Therapy with Ranibizumab in Wet Age-Related Macular DegenerationAlfredo García-Layana0Marta S. Figueroa1Luis Arias2Javier Araiz3José María Ruiz-Moreno4José García-Arumí5Francisco Gómez-Ulla6María Isabel López-Gálvez7Francisco Cabrera-López8José Manuel García-Campos9Jordi Monés10Enrique Cervera11Felix Armadá12Roberto Gallego-Pinazo13Clínica Universidad de Navarra, Avenida de Pío XII 36, 31008 Pamplona, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainSociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, SpainIndividualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the patient is treated in the presence of signs of lesion activity. Therefore, an early detection of reactivation of the disease with immediate retreatment is crucial to prevent visual acuity loss. Several trials suggest that “treat and extend” and other proactive regimens provide a reasonable approach. The rationale of the proactive regimens is to perform treatment anticipating relapses or recurrences and therefore avoid drops in vision while individualizing patient followup. Treat and extend study results in significant direct medical cost savings from fewer treatments and office visits compared to monthly treatment. Current data suggest that, for one year, PRN is less expensive, but treat and extend regimen would likely be less expensive for subsequent years. Once a patient is not a candidate to continue with treatment, he/she should be sent to an outpatient unit with adequate resources to follow nAMD patients in order to reduce the burden of specialized ophthalmologist services.http://dx.doi.org/10.1155/2015/412903 |
| spellingShingle | Alfredo García-Layana Marta S. Figueroa Luis Arias Javier Araiz José María Ruiz-Moreno José García-Arumí Francisco Gómez-Ulla María Isabel López-Gálvez Francisco Cabrera-López José Manuel García-Campos Jordi Monés Enrique Cervera Felix Armadá Roberto Gallego-Pinazo Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration Journal of Ophthalmology |
| title | Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration |
| title_full | Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration |
| title_fullStr | Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration |
| title_full_unstemmed | Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration |
| title_short | Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration |
| title_sort | individualized therapy with ranibizumab in wet age related macular degeneration |
| url | http://dx.doi.org/10.1155/2015/412903 |
| work_keys_str_mv | AT alfredogarcialayana individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT martasfigueroa individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT luisarias individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT javieraraiz individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT josemariaruizmoreno individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT josegarciaarumi individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT franciscogomezulla individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT mariaisabellopezgalvez individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT franciscocabreralopez individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT josemanuelgarciacampos individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT jordimones individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT enriquecervera individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT felixarmada individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration AT robertogallegopinazo individualizedtherapywithranibizumabinwetagerelatedmaculardegeneration |